ClinConnect ClinConnect Logo
Search / Trial NCT04496687

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

Launched by SCAD ALLIANCE · Jul 29, 2020

Trial Information

Current as of July 21, 2025

Recruiting

Keywords

Spontaneous Coronary Artery Dissection (Scad) Myocardial Infarction Sudden Cardiac Arrest Acute Coronary Syndrome

ClinConnect Summary

The iSCAD Registry is an international study focused on understanding and improving care for people diagnosed with Spontaneous Coronary Artery Dissection (SCAD). SCAD is a condition where a tear forms in the artery wall, which can lead to serious heart problems. The main goal of this study is to gather information from participants to help develop better practices and guidelines for preventing SCAD and its recurrence. Researchers are actively recruiting individuals who are 18 years and older and have either a new diagnosis of SCAD or a history of it. Participants can be recruited from hospitals during their treatment or from outpatient heart clinics.

If you choose to participate, you'll be asked to provide information about your health and experiences related to SCAD. This study will help researchers learn more about how SCAD affects patients over time and how best to manage it. It's important to note that certain individuals, such as those with SCAD related to other conditions or who cannot provide informed consent, may not be eligible to join. Your participation could contribute to advancements in understanding and treating SCAD, ultimately benefiting patients in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants with a new diagnosis of SCAD or a history of confirmed or suspected SCAD will be prospectively recruited from either:
  • 1. Inpatient wards of the enrolling medical centers during the acute presentation of SCAD, or
  • 2. Outpatient cardiovascular clinics of enrolling medical centers.
  • Participants must be:
  • 18 years of age or older
  • Diagnosis of SCAD or history of SCAD based on coronary angiography, either catheter-based or coronary CTA
  • Suspected SCAD by coronary angiography
  • Exclusion Criteria:
  • 1. Coronary dissection in association with atherosclerosis or as a result of iatrogenic injury
  • 2. Inability to provide informed consent
  • 3. Inability to complete study-related patient questionnaires
  • 4. Inability to understand and complete patient questionnaires independently

About Scad Alliance

SCAD Alliance is a dedicated research organization focused on advancing the understanding and treatment of Spontaneous Coronary Artery Dissection (SCAD), a rare but serious condition that can lead to heart attacks, particularly in women. Comprising a team of experts in cardiology, genetics, and patient advocacy, SCAD Alliance is committed to fostering innovative clinical trials that explore the underlying mechanisms of SCAD, improve diagnostic methods, and develop effective therapies. By collaborating with healthcare professionals and leveraging patient insights, SCAD Alliance aims to enhance awareness, improve patient outcomes, and drive significant advancements in the management of this complex cardiovascular disorder.

Locations

Boston, Massachusetts, United States

Philadelphia, Pennsylvania, United States

Lexington, Kentucky, United States

New York, New York, United States

Charlottesville, Virginia, United States

Pittsburgh, Pennsylvania, United States

Hartford, Connecticut, United States

Nashville, Tennessee, United States

Dallas, Texas, United States

Saint Louis, Missouri, United States

Aurora, Colorado, United States

Tampa, Florida, United States

Charlottesville, Virginia, United States

Lexington, Kentucky, United States

Oklahoma City, Oklahoma, United States

Manchester, New Hampshire, United States

Baltimore, Maryland, United States

Los Angeles, California, United States

Lebanon, New Hampshire, United States

San Francisco, California, United States

Chicago, Illinois, United States

Tampa, Florida, United States

Seattle, Washington, United States

New York, New York, United States

Murray, Utah, United States

Los Angeles, California, United States

Atlanta, Georgia, United States

Kansas City, Missouri, United States

Cleveland, Ohio, United States

Portland, Oregon, United States

Charlotte, North Carolina, United States

Darlinghurst, New South Wales, Australia

Pittsburgh, Pennsylvania, United States

Fairfax, Virginia, United States

Patients applied

0 patients applied

Trial Officials

Esther Kim, MD

Study Chair

Chair, Steering Committee

Malissa Wood, MD

Principal Investigator

Member, Steering Committee

Sahar Naderi, MD

Principal Investigator

Member, Steering Committee

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials